The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: Concerns over the use of total-body irradiation in systemic sclerosis

R. K. Burt, K. Kallunian, D. Patel, J. Thomas, Andrew M Yeager, A. Traynor, F. Heipe, R. Arnold, A. Marmont, D. Collier, E. Glatstein, J. Snowden

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly recognized indication for treatment of autoimmune diseases and severe immune-mediated disorders. However, multicenter registry data have demonstrated higher than anticipated early toxicity, approximately 10% for autoimmune diseases in general, and 20-27% for diffuse systemic sclerosis (scleroderma). If uncorrected, this high treatment-related mortality will hinder development of stem cell therapy for immune-mediated diseases. In order to develop safer regimens, we address some pitfalls and concepts involved in design and selection of conditioning regimens for autoimmune diseases in general, and because it is associated with the highest regimen-related toxicity, scleroderma in specific.

Original languageEnglish (US)
Pages (from-to)745-751
Number of pages7
JournalBone Marrow Transplantation
Volume34
Issue number9
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Whole-Body Irradiation
Systemic Scleroderma
Hematopoietic Stem Cells
Autoimmune Diseases
Immune System Diseases
Transplants
Diffuse Scleroderma
Hematopoietic Stem Cell Transplantation
Cell- and Tissue-Based Therapy
Registries
Stem Cells
Mortality
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens : Concerns over the use of total-body irradiation in systemic sclerosis. / Burt, R. K.; Kallunian, K.; Patel, D.; Thomas, J.; Yeager, Andrew M; Traynor, A.; Heipe, F.; Arnold, R.; Marmont, A.; Collier, D.; Glatstein, E.; Snowden, J.

In: Bone Marrow Transplantation, Vol. 34, No. 9, 11.2004, p. 745-751.

Research output: Contribution to journalArticle

Burt, RK, Kallunian, K, Patel, D, Thomas, J, Yeager, AM, Traynor, A, Heipe, F, Arnold, R, Marmont, A, Collier, D, Glatstein, E & Snowden, J 2004, 'The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: Concerns over the use of total-body irradiation in systemic sclerosis', Bone Marrow Transplantation, vol. 34, no. 9, pp. 745-751. https://doi.org/10.1038/sj.bmt.1704671
Burt, R. K. ; Kallunian, K. ; Patel, D. ; Thomas, J. ; Yeager, Andrew M ; Traynor, A. ; Heipe, F. ; Arnold, R. ; Marmont, A. ; Collier, D. ; Glatstein, E. ; Snowden, J. / The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens : Concerns over the use of total-body irradiation in systemic sclerosis. In: Bone Marrow Transplantation. 2004 ; Vol. 34, No. 9. pp. 745-751.
@article{76d7b65be7a84bdcb6990c37a9fb9ef2,
title = "The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: Concerns over the use of total-body irradiation in systemic sclerosis",
abstract = "Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly recognized indication for treatment of autoimmune diseases and severe immune-mediated disorders. However, multicenter registry data have demonstrated higher than anticipated early toxicity, approximately 10{\%} for autoimmune diseases in general, and 20-27{\%} for diffuse systemic sclerosis (scleroderma). If uncorrected, this high treatment-related mortality will hinder development of stem cell therapy for immune-mediated diseases. In order to develop safer regimens, we address some pitfalls and concepts involved in design and selection of conditioning regimens for autoimmune diseases in general, and because it is associated with the highest regimen-related toxicity, scleroderma in specific.",
author = "Burt, {R. K.} and K. Kallunian and D. Patel and J. Thomas and Yeager, {Andrew M} and A. Traynor and F. Heipe and R. Arnold and A. Marmont and D. Collier and E. Glatstein and J. Snowden",
year = "2004",
month = "11",
doi = "10.1038/sj.bmt.1704671",
language = "English (US)",
volume = "34",
pages = "745--751",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens

T2 - Concerns over the use of total-body irradiation in systemic sclerosis

AU - Burt, R. K.

AU - Kallunian, K.

AU - Patel, D.

AU - Thomas, J.

AU - Yeager, Andrew M

AU - Traynor, A.

AU - Heipe, F.

AU - Arnold, R.

AU - Marmont, A.

AU - Collier, D.

AU - Glatstein, E.

AU - Snowden, J.

PY - 2004/11

Y1 - 2004/11

N2 - Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly recognized indication for treatment of autoimmune diseases and severe immune-mediated disorders. However, multicenter registry data have demonstrated higher than anticipated early toxicity, approximately 10% for autoimmune diseases in general, and 20-27% for diffuse systemic sclerosis (scleroderma). If uncorrected, this high treatment-related mortality will hinder development of stem cell therapy for immune-mediated diseases. In order to develop safer regimens, we address some pitfalls and concepts involved in design and selection of conditioning regimens for autoimmune diseases in general, and because it is associated with the highest regimen-related toxicity, scleroderma in specific.

AB - Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly recognized indication for treatment of autoimmune diseases and severe immune-mediated disorders. However, multicenter registry data have demonstrated higher than anticipated early toxicity, approximately 10% for autoimmune diseases in general, and 20-27% for diffuse systemic sclerosis (scleroderma). If uncorrected, this high treatment-related mortality will hinder development of stem cell therapy for immune-mediated diseases. In order to develop safer regimens, we address some pitfalls and concepts involved in design and selection of conditioning regimens for autoimmune diseases in general, and because it is associated with the highest regimen-related toxicity, scleroderma in specific.

UR - http://www.scopus.com/inward/record.url?scp=7944225009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944225009&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704671

DO - 10.1038/sj.bmt.1704671

M3 - Article

C2 - 15361910

AN - SCOPUS:7944225009

VL - 34

SP - 745

EP - 751

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -